Publication|Articles|December 18, 2024
- Pharmaceutical Executive: December 2024
- Volume 44
- Issue 12
Pharmaceutical Executive: December 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive December 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 1 year ago
Trending Forwardover 1 year ago
Pharma’s ‘Best-Kept Secret’over 1 year ago
Seeking More Value, Less Costover 1 year ago
Dealmaking Dormant No Moreover 1 year ago
A Rocky Road for Regulationover 1 year ago
DTC's New Era of Engagementover 1 year ago
Holding On Tight to AI Waveover 1 year ago
The Recipe for Relief: Overcoming Industry Pain Pointsover 1 year ago
Pharma Forecasting: Key Markets Investors Can’t IgnoreAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly’s Foundayo and Lower-Dose Zepbound Helped Maintain Weight Loss in Patients Switching from Injectables
2
Pharmaceutical Executive Daily: Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu
3
Rigel Pharmaceuticals Enters $85 Million Agreement for Exclusive Global Rights to Veppanu
4
FDA Approves Beqalzi for Relapsed or Refractory Mantle Cell Lymphoma, Inqovi in Combination with Venetoclax
5